Limited success of current HIV-1 vaccines warrants new approaches. We discuss feasibility and potential benefits of early life HIV-1 immunization followed by vaccine boosts during childhood that may enable maturation of vaccine-induced broad anti-HIV-1 immunity over several years. By initiating this immunization approach in the very young, well before sexual debut, such a strategy may dramatically reduce the risk of HIV-1 infection.
Get full access to this article
View all access options for this article.
References
1.
SafritJT, TomarasGD, HankeT, deCampAC, VoroninY: The landscape of targeted immune responses in the HIV-1 vaccine field. AIDS Res Hum Retroviruses, 2016; 32:944–946.
2.
Abdool KarimQ, BaxterC, BirxD: Prevention of HIV in adolescent girls and young women: Key to an AIDS-free generation. J Acquir Immune Defic Syndr, 2017; 75(Suppl 1):S17–S26.
3.
HarrisonA, ColvinCJ, KuoC, SwartzA, LurieM: Sustained high HIV incidence in young women in Southern Africa: Social, behavioral, and structural factors and emerging intervention approaches. Curr HIV AIDS Rep, 2015; 12:207–215.
4.
Irewole-OjoFO, SenbanjoIO, OduwoleAO, NjokanmaOF: Age of pubertal events among school girls in Lagos, Nigeria. J Pediatr Endocrinol Metab, 2018; 31:313–321.
5.
EspositoS, PrincipiN, CornagliaG; ESCMID Vaccine Study Group (EVASG). Barriers to the vaccination of children and adolescents and possible solutions. Clin Microbiol Infect, 2014; 20(Suppl 5):25–31.
6.
GableJ, EderJ, NoonanK, FeemsterK: Increasing HPV Vaccination Rates Among Adolescents: Challenges and Opportunities. The Children's Hospital of Philadelphia, Philadelphia, PA, 2015.
7.
KollmannTR, KampmannB, MazmanianSK, MarchantA, LevyO: Protecting the newborn and young infant from infectious diseases: Lessons from immune ontogeny. Immunity, 2017; 46:350–363.
8.
KnudsenNP, OlsenA, BuonsantiC, et al.: Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep, 2016; 6:19570.
9.
GarconN, Di PasqualeA: From discovery to licensure, the Adjuvant System story. Hum Vaccin Immunother, 2017; 13:19–33.
10.
GorielyS, VincartB, StordeurP, et al.: Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol, 2001; 166:2141–2146.
11.
GorielyS, Van LintC, DadkhahR, et al.: A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J Exp Med, 2004; 199:1011–1016.
12.
Vanden EijndenS, GorielyS, De WitD, GoldmanM, WillemsF: Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns. Eur J Immunol, 2006; 36:21–26.
13.
LevyO, ZaremberKA, RoyRM, CywesC, GodowskiPJ, WesselsMR: Selective impairment of TLR-mediated innate immunity in human newborns: Neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol, 2004; 173:4627–4634.
14.
TourneurE, ChassinC: Neonatal immune adaptation of the gut and its role during infections. Clin Dev Immunol, 2013; 2013:270301.
15.
LynnDJ, PulendranB: The potential of the microbiota to influence vaccine responses. J Leukoc Biol, 2017; 103:225–231.
16.
WilliamsWB, LiaoHX, MoodyMA, et al.: HIV-1 vaccines. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015; 349:aab1253.
17.
DowlingDJ, van HarenSD, et al.: TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. JCI Insight, 2017; 2:e91020.
18.
BreitfeldD, OhlL, KremmerE, et al.: Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med, 2000; 192:1545–1552.
19.
SchaerliP, WillimannK, LangAB, LippM, LoetscherP, MoserB: CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med, 2000;192:1553–1562.
20.
MastelicB, KamathAT, FontannazP, et al.: Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. J Immunol, 2012; 189:5764–5772.
21.
XuH, WangX, LacknerAA, VeazeyRS: PD-1(HIGH) follicular CD4 T helper cell subsets residing in lymph node germinal centers correlate with B cell maturation and IgG production in Rhesus macaques. Front Immunol, 2014; 5:85.
22.
BorrielloF, PietrasantaC, LaiJCY, et al.: Identification and characterization of stimulator of interferon genes as a robust adjuvant target for early life immunization. Front Immunol, 2017; 8:1772.
23.
van HarenSD, DowlingDJ, FoppenW, et al.: Age-specific adjuvant synergy: Dual TLR7/8 and mincle activation of human newborn dendritic cells enables Th1 polarization. J Immunol, 2016; 197:4413–4424.
24.
FoudaGG, CunninghamCK, McFarlandEJ, et al.: Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. J Infect Dis, 2015; 211:508–517.
25.
GooL, ChohanV, NduatiR, OverbaughJ: Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med, 2014; 20:655–658.
26.
SimonichCA, WilliamsKL, VerkerkeHP, et al.: HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell, 2016; 166:77–87.
27.
ChungAW, GhebremichaelM, RobinsonH, et al.: Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med, 2014; 6:228ra38.
28.
SiegristCA: Neonatal and early life vaccinology. Vaccine, 2001; 19:3331–3346.
29.
BakerCA, SwainsonL, LinDL, et al.: Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge. Sci Transl Med, 2015; 7:300ra125.
30.
AckermanME, BarouchDH, AlterG: Systems serology for evaluation of HIV vaccine trials. Immunol Rev, 2017; 275:262–270.
31.
BrownEP, DowellKG, BoeschAW, et al.: Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods, 2017; 443:33–44.
32.
VaradarajanN, KwonDS, LawKM, et al.: Rapid, efficient functional characterization and recovery of HIV-specific human CD8+ T cells using microengraving. Proc Natl Acad Sci U S A, 2012; 109:3885–3890.
33.
GiladiA, AmitI: Immunology, one cell at a time. Nature, 2017; 547:27–29.
34.
OhDY, DowlingDJ, AhmedS, et al.: Adjuvant-induced human monocyte secretome profiles reveal adjuvant- and age-specific protein signatures. Mol Cell Proteomics, 2016; 15:1877–1894.
35.
KazminD, NakayaHI, LeeEK, et al.: Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. Proc Natl Acad Sci U S A, 2017; 114:2425–2430.
36.
van den BergRA, CocciaM, BallouWR, et al.: Predicting RTS,S vaccine-mediated protection from transcriptomes in a malaria-challenge clinical trial. Front Immunol, 2017; 8:557.
37.
PettengillMA, LevyO: Circulating human neonatal naive B cells are deficient in CD73 impairing purine salvage. Front Immunol, 2016; 7:121.
38.
HessellAJ, HaigwoodNL: Animal models in HIV-1 protection and therapy. Curr Opin HIV AIDS, 2015; 10:170–176.
39.
Van RompayKK, AbelK, LawsonJR, et al.: Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr, 2005; 38:124–134.
40.
Van RompayKK, CherringtonJM, MarthasML, et al.: 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant Rhesus macaques. Antimicrob Agents Chemother, 1996; 40:2586–2591.
41.
Van RompayKK, BerardiCJ, Dillard-TelmS, et al.: Passive immunization of newborn Rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis, 1998; 177:1247–1259.
42.
HessellAJ, JaworskiJP, EpsonE, et al.: Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med, 2016; 22:362–368.
43.
KeplerTB, WieheK: Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. Immunol Rev, 2017; 275:129–144.
